By 2018, nearly half of all TMVR patients were going home the very next day. Outcomes for these patients have been consistently positive. 

The study's authors examined outcomes data from more than 8,500 tricuspid valve repairs and nearly 9,000 tricuspid valve replacements.

The device has already been approved in other parts of the world, including Europe. 

Overall, the authors emphasized, TMVR helped heart failure patients with and without diabetes.

Researchers tracked data from nearly 2,500 patients from 15 different facilities, sharing their findings in the Journal of the American College of Cardiology.

Cardiogenic shock has been linked to a heightened risk of morbidity and mortality. TEER, it seems, may be able to help provide patients with some relief. 

The new analysis, published in JACC: Heart Failure, focused on patient data from the renowned COAPT trial.